Omeros Corporation Common Stock (OMER)

FairStock Score: 37/100 — MIXED

Key Financials

Strengths

• Generates $181 million in annual free cash flow (18.8% yield on market cap)
• Superior net profit margin of 873.9% indicating pricing power and operational efficiency

Concerns

• Weak Piotroski F-Score of 2/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of -2.1 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Omeros Corporation Common Stock is a micro-cap healthcare company valued at $963 million. The business generates $10 million in annual revenue with a 873.9% net margin and $181 million in free cash flow. From a quality standpoint, Omeros shows weak Piotroski F-Score of 2/9 signaling deteriorating fundamentals and distressed Altman Z-Score of -2.1 warrants caution. On valuation, the stock is attractively valued at 10.8x earnings, with PEG of 0.03 suggests growth is underpriced. Growth dynamics show profit growth of 375.7%. Our composite FairStock Score of 37/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $181 million in annual free cash flow (18.8% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer